Death · Patients with severe malaria
The fixed-effect NMR reported a difference between artemether and quinine at ages 15 years or more; no GRADE assessment was reported.
2 findings from 1 review
no estimate extracted
Studies not reported
GRADE not reported
no estimate extracted
Studies not reported
GRADE not reported
Proportion of healthcare workers who reported a stockout of drugs in the last 30 days (stockout of artemether‐lumefantrine 2 X 6 to treat malaria caused by Plasmodium facilparum) · healthcare workers and other health professionals involved in commodity and stock management
It is very uncertain whether primary objective: mobile stock notification with effective product… changes proportion of healthcare workers who reported a stockout of drugs in… compared with standard care (very low certainty).
1 finding from 1 review
RR 1.43 [0.81, 2.5]
168 participants
Very low
Proportion of healthcare workers who reported a stockout of drugs in the last 30 days (stockout of artemether‐lumefantrine 2 X 6 to treat malaria caused by Plasmodium facilparum) · healthcare workers and other health professionals involved in commodity and stock management
It is very uncertain whether primary objective: mobile stock notification with enhanced management changes proportion of healthcare workers who reported a stockout of drugs in… compared with standard care (very low certainty).
1 finding from 1 review
RR 0.72 [0.36, 1.44]
171 participants
Very low
Total failure: day 28 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 28 (PCR‐adjusted) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
Total failure: day 42 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 42 (PCR‐adjusted) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
Total failure: day 28 (unadjusted) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) may leads to lower total failure: day 28 (unadjusted) compared with artemether‐lumefantrine (AL) (low certainty).
2 findings from 1 review
Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) may leads to higher first treatment, abnormal ALT increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) may leads to higher first treatment, abnormal AST increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal bilirubin increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
Total failure: day 28 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artemether‐lumefantrine (low certainty).
1 finding from 1 review
Total failure day 42 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artemether‐lumefantrine (low certainty).
1 finding from 1 review
Total failure: day 42 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐adjusted compared with artemether‐lumefantrine (low certainty).
1 finding from 1 review
Death · Patients with severe malaria
In the illustrative network meta-regression no difference in the log odds ratio for death between artesunate and artemether was seen at any displayed average age; certainty was not graded.
1 finding from 1 review
no estimate extracted
Studies not reported
GRADE not reported
Treatment failure Day 28 · adults and children with uncomplicated P falciparum malaria
Dihydroartemisinin‐piperaquine leads to lower treatment failure Day 28 compared with artemether‐lumefantrine (high certainty).
1 finding from 1 review
Treatment failure Day 63 · adults and children with uncomplicated P falciparum malaria
Dihydroartemisinin‐piperaquine leads to lower treatment failure Day 63 compared with artemether‐lumefantrine (high certainty).
1 finding from 1 review
Intervention not reported
Death · children with severe malaria
The intervention showed no clear difference in death (moderate certainty).
1 finding from 1 review
Intervention not reported
Fever clearance time · adults with severe malaria
1 finding from 1 review
Intervention not reported
Death · adults with severe malaria
The intervention probably leads to higher death (moderate certainty).
1 finding from 1 review
Intervention not reported
Coma resolution time · adults with severe malaria
1 finding from 1 review